Loading…
Reported covered position: Health Policy Advisor, Senator Bill Cassidy; Legislative Assistant/Sr. Legislative Assistant/Legislative Correspondent, Representative Larry Bucshon
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program.
Client: NOVARTIS, INC. · Firm: TODD STRATEGY GROUP
Center for Medicare and Medicaid Innovation (CMMI) policy issues. Drug Pricing. General Medicare and Medicaid Issues. Implementation of Inflation Reduction Act of 2022. H.R.1672 - Maintaining Investments in New Innovation Act. S.3131 / H.R.5539 - ORPHAN Cures Act. S.832/H.R.1492: Ensuring Pathways to Innovative Cures Act of 2025 or the EPIC Act of 2025.
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
TAKEDA PHARMACEUTICALS AMERICA, INC. via TODD STRATEGY GROUP
2025 · third_quarter · Q3
Rare Disease Issues.
General Medicare/Medicaid Issues. Implementation of Inflation Reduction Act of 2022.
Filing targets: HOUSE OF REPRESENTATIVES
Source: Senate LDA
| GENENTECH INC |
| 19 |
| 2021–2025 |
| ALEXION PHARMACEUTICALS, INC. | 18 | 2021–2025 |
| BIOGEN, INC. | 18 | 2021–2025 |
| HOSPICE COMPASSUS | 18 | 2021–2025 |
| GILEAD SCIENCES, INC. | 17 | 2022–2025 |
| MCKESSON CORPORATION | 17 | 2021–2025 |
| OTSUKA AMERICA PHARMACEUTICAL, INC. | 17 | 2021–2025 |
| SIEMENS HEALTHINEERS | 17 | 2021–2025 |
| NOVARTIS, INC. | 16 | 2022–2025 |
| Alnylam Pharmaceuticals, Inc. | 15 | 2022–2025 |
| MERCK & CO., INC. | 15 | 2022–2025 |
| PMI US CORPORATE SERVICES INC. | 15 | 2023–2025 |
| ADULT VACCINE ACCESS COALITION | 14 | 2022–2024 |
| MYRIAD GENETICS INC | 14 | 2022–2025 |
| VAXESS TECHNOLOGIES, INC | 14 | 2021–2024 |
| BRISTOL-MYERS SQUIBB COMPANY | 13 | 2023–2025 |
| OSRX PHARMACEUTICALS | 13 | 2023–2025 |
| AMERICAN MEDICAL ASSOCIATION | 12 | 2023–2025 |
| FERRING PHARMACEUTICALS, INC. | 12 | 2023–2025 |
| NOVO NORDISK, INC. | 12 | 2023–2025 |
| ALLIANCE FOR CELL THERAPY NOW | 11 | 2021–2023 |
| GRAIL, Inc. | 11 | 2021–2024 |
| PUERTO RICO DEPARTMENT OF HEALTH | 11 | 2022–2025 |
| JOHNSON & JOHNSON SERVICES, INC. | 10 | 2023–2025 |
| MEDICAL COUNTERMEASURES COALITION | 10 | 2024–2025 |
| THE ORTHOFORUM | 10 | 2023–2025 |
| TRUIST FINANCIAL CORPORATION | 10 | 2023–2025 |
| AMERICAN POLICY VENTURES ACTION | 9 | 2024–2025 |
| EMD SERONO, INC. | 9 | 2023–2025 |
| EXELIXIS, INC. | 9 | 2023–2025 |
| KARIUS, INC. | 9 | 2022–2024 |
| NOMI HEALTH, INC. | 9 | 2024–2025 |
| PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA | 9 | 2023–2025 |
| SOUTHWEST TRANSPLANT ALLIANCE | 9 | 2023–2025 |
| AMERICAN COLLEGE OF RADIOLOGY | 8 | 2023–2025 |
| ASTRAZENECA PHARMACEUTICALS LP | 8 | 2021–2023 |
| GENMAB | 8 | 2023–2025 |
| HEALTH SUPPLY US LLC | 8 | 2023–2024 |
| ILLUMINA, INC. | 8 | 2023–2025 |
| SYNTHETIC BIOLOGY COALITION | 8 | 2021–2022 |
| TAKEDA PHARMACEUTICALS AMERICA INC | 8 | 2023–2025 |
| UCB, INC. | 8 | 2022–2023 |
| VERACYTE, INC. | 8 | 2021–2022 |
| ASTELLAS PHARMA US, INC. | 7 | 2024–2025 |
| BIOTECHNOLOGY INNOVATION ORGANIZATION | 7 | 2023–2024 |
| DH DIAGNOSTICS, LLC | 7 | 2024–2025 |
| ELI LILLY AND COMPANY | 7 | 2024–2025 |
| GINKGO BIOSECURITY | 7 | 2023–2025 |
| NETLIST, INC. | 7 | 2023–2025 |
| APOLLO GLOBAL MANAGEMENT | 6 | 2023–2025 |
| AVS BIO | 6 | 2024 |
| BLUE NOTE THERAPEUTICS | 6 | 2022–2023 |
| CAREDX, INC. | 6 | 2021–2022 |
| CORMEDIX, INC. | 6 | 2023–2024 |
| FOX CORPORATION | 6 | 2023–2025 |
| KALDEROS, INC. | 6 | 2024–2025 |
| ORGANIZE.ORG | 6 | 2021–2022 |
| PUERTO RICO FINANCIAL AND FISCAL AUTHORITY | 6 | 2022–2023 |
| U.S. CHAMBER OF COMMERCE GLOBAL INNOVATION POLICY CENTER | 6 | 2024–2025 |
| AMERICAN SOCIETY OF NEPHROLOGY | 5 | 2024–2025 |
| Cepheid | 5 | 2023–2024 |
| MED CLAIMS COMPLIANCE CORPORATION | 5 | 2022–2025 |
| MUTUAL OF OMAHA | 5 | 2024–2025 |
| VIFOR PHARMA INC | 5 | 2021–2022 |
| EMD MILLIPORE | 4 | 2023 |
| FLEXCARE | 4 | 2024–2025 |
| GLAXOSMITHKLINE LLC | 4 | 2025 |
| PFIZER, INC. | 4 | 2023 |
| VANTIVE US HEALTHCARE LLC | 4 | 2025 |
| VARIAN MEDICAL SYSTEMS, INC. | 4 | 2021 |
| HORIZON THERAPEUTICS USA, INC. | 2 | 2023 |
Patents. Support for PREVAIL Act. Support for H.R.1574 - RESTORE Patent Rights Act of 2025.
Maintaining Investments in New Innovation Act
Client: ALEXION PHARMACEUTICALS, INC. · Firm: TODD STRATEGY GROUP
General issues related to rare disease and orphan drugs. Diagnostics for patients with rare disease. Multi-Cancer Early Detection. H.R.1672 - Maintaining Investments in New Innovation Act. H.R.946 - ORPHAN Cures Act.
Maintaining Investments in New Innovation Act
Client: ALNYLAM PHARMACEUTICALS, INC. · Firm: TODD STRATEGY GROUP
Medicare and Medicaid Issues H.R.1672 - Maintaining Investments in New Innovation Act. H.R.946 - ORPHAN Cures Act. Home infusion.
Maintaining Investments in New Innovation Act
Client: ALNYLAM PHARMACEUTICALS, INC. · Firm: TODD STRATEGY GROUP
Medicare and Medicaid Issues H.R.1672 - Maintaining Investments in New Innovation Act. H.R.946 - ORPHAN Cures Act.
Maintaining Investments in New Innovation Act
Client: ALEXION PHARMACEUTICALS, INC. · Firm: TODD STRATEGY GROUP
General issues related to rare disease and orphan drugs. Diagnostics for patients with rare disease. Multi-Cancer Early Detection. H.R.1672 - Maintaining Investments in New Innovation Act. H.R.946 - ORPHAN Cures Act.
Maintaining Investments in New Innovation Act
Client: NOVARTIS, INC. · Firm: TODD STRATEGY GROUP
Center for Medicare and Medicaid Innovation (CMMI) policy issues. Drug Pricing. General Medicare and Medicaid Issues. Implementation of Inflation Reduction Act of 2022. H.R.1672 - Maintaining Investments in New Innovation Act. S.3131 / H.R.5539 - ORPHAN Cures Act. S.832 - EPIC Act of 2025.
Maintaining Investments in New Innovation Act
Client: ALNYLAM PHARMACEUTICALS, INC. · Firm: TODD STRATEGY GROUP
Medicare and Medicaid Issues H.R.1672 - Maintaining Investments in New Innovation Act. H.R.946 - ORPHAN Cures Act.
Maintaining Investments in New Innovation Act
Client: NOVARTIS, INC. · Firm: TODD STRATEGY GROUP
Center for Medicare and Medicaid Innovation (CMMI) policy issues. Drug Pricing. General Medicare and Medicaid Issues. Implementation of Inflation Reduction Act of 2022. H.R.1672 - Maintaining Investments in New Innovation Act. S.3131 / H.R.5539 - ORPHAN Cures Act. S.832/H.R.1492: Ensuring Pathways to Innovative Cures Act of 2025 or the EPIC Act of 2025.
Maintaining Investments in New Innovation Act
Client: ALEXION PHARMACEUTICALS, INC. · Firm: TODD STRATEGY GROUP
General issues related to rare disease and orphan drugs. Diagnostics for patients with rare disease. Multi-Cancer Early Detection. H.R.1672 - Maintaining Investments in New Innovation Act. H.R.946 - ORPHAN Cures Act.
General issues related to rare disease and orphan drugs. Diagnostics for patients with rare disease. Multi-Cancer Early Detection. H.R.1672 - Maintaining Investments in New Innovation Act. H.R.946 - ORPHAN Cures Act.
General issues related to rare disease and orphan drugs. Diagnostics for patients with rare disease. Multi-Cancer Early Detection. H.R.1672 - Maintaining Investments in New Innovation Act. H.R.946 - ORPHAN Cures Act.
General issues related to rare disease and orphan drugs. Diagnostics for patients with rare disease. Multi-Cancer Early Detection. H.R.1672 - Maintaining Investments in New Innovation Act. H.R.946 - ORPHAN Cures Act.
Medicare and Medicaid Issues H.R.1672 - Maintaining Investments in New Innovation Act. H.R.946 - ORPHAN Cures Act. Home infusion.
Medicare and Medicaid Issues H.R.1672 - Maintaining Investments in New Innovation Act. H.R.946 - ORPHAN Cures Act.
Medicare and Medicaid Issues H.R.1672 - Maintaining Investments in New Innovation Act. H.R.946 - ORPHAN Cures Act.
Center for Medicare and Medicaid Innovation (CMMI) policy issues. Drug Pricing. General Medicare and Medicaid Issues. Implementation of Inflation Reduction Act of 2022. H.R.1672 - Maintaining Investments in New Innovation Act. S.3131 / H.R.5539 - ORPHAN Cures Act. S.832 - EPIC Act of 2025.
Center for Medicare and Medicaid Innovation (CMMI) policy issues. Drug Pricing. General Medicare and Medicaid Issues. Implementation of Inflation Reduction Act of 2022. H.R.1672 - Maintaining Investments in New Innovation Act. S.3131 / H.R.5539 - ORPHAN Cures Act. S.832/H.R.1492: Ensuring Pathways to Innovative Cures Act of 2025 or the EPIC Act of 2025.
Pharmacy Benefit Managers. 340B. Tort Litigation reform. Health care supply chain. S.864 - HELP Copays Act. Inflation Reduction Act Implementation.
Pharmacy Benefit Managers. 340B. Tort Litigation reform. Health care supply chain. S.864 - HELP Copays Act. Inflation Reduction Act Implementation.
HELP Copays Act
Client: PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA · Firm: TODD STRATEGY GROUP
Part D changes. Prescription drug payment reform. 340B issues. Onshoring. S.864 - HELP Copays Act. General Medicare and Medicaid Issues.
HELP Copays Act
Client: PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA · Firm: TODD STRATEGY GROUP
Part D changes. Prescription drug payment reform. 340B issues. Onshoring. S.864 - HELP Copays Act. General Medicare and Medicaid Issues.
Drug Pricing. S.864 - HELP Copays Act.
340B Program. Home Infusion for Part B Products. S.864 - HELP Copays Act. Medicare Reimbursement for New Technologies.
340B Program. Home Infusion for Part B Products. S.864 - HELP Copays Act. Medicare Reimbursement for New Technologies.
340B Program. Home Infusion for Part B Products. S.864 - HELP Copays Act. Medicare Reimbursement for New Technologies.
Pharmacy Benefit Managers. 340B. Tort Litigation reform. Health care supply chain. S.864 - HELP Copays Act. Inflation Reduction Act Implementation.
HELP Copays Act
Client: PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA · Firm: TODD STRATEGY GROUP
Part D changes. Prescription drug payment reform. 340B issues. Onshoring. S.864 - HELP Copays Act. General Medicare and Medicaid Issues.
Drug Pricing. S.864 - HELP Copays Act.
Drug Pricing. S.864 - HELP Copays Act.
Consumer-directed health care and transparency. H.R.5378 - Lower Costs, More Transparency Act.
Center for Medicare and Medicaid Innovation (CMMI) policy issues. Drug Pricing. General Medicare and Medicaid Issues. Implementation of Inflation Reduction Act of 2022. H.R.1672 - Maintaining Investments in New Innovation Act. S.3131 / H.R.5539 - ORPHAN Cures Act. S.832/H.R.1492: Ensuring Pathways to Innovative Cures Act of 2025 or the EPIC Act of 2025.
Center for Medicare and Medicaid Innovation (CMMI) policy issues. Drug Pricing. General Medicare and Medicaid Issues. Implementation of Inflation Reduction Act of 2022. H.R.1672 - Maintaining Investments in New Innovation Act. S.3131 / H.R.5539 - ORPHAN Cures Act. S.832 - EPIC Act of 2025.
Center for Medicare and Medicaid Innovation (CMMI) policy issues. Drug Pricing. General Medicare and Medicaid Issues. Implementation of Inflation Reduction Act of 2022. H.R.1672 - Maintaining Investments in New Innovation Act. S.3131 / H.R.5539 - ORPHAN Cures Act. S.832/H.R.1492: Ensuring Pathways to Innovative Cures Act of 2025 or the EPIC Act of 2025.
Center for Medicare and Medicaid Innovation (CMMI) policy issues. Drug Pricing. General Medicare and Medicaid Issues. Implementation of Inflation Reduction Act of 2022. H.R.1672 - Maintaining Investments in New Innovation Act. S.3131 / H.R.5539 - ORPHAN Cures Act. S.832 - EPIC Act of 2025.
Center for Medicare and Medicaid Innovation (CMMI) policy issues. Drug Pricing. General Medicare and Medicaid Issues. Implementation of Inflation Reduction Act of 2022. H.R.1672 - Maintaining Investments in New Innovation Act. H.R.946 - ORPHAN Cures Act.
Supply Chain. 340B Issues. Outcomes based contracting/value-based arrangements. Genetically Targeted Therapies. PBM policy issues. H.R.5376 - Inflation Reduction Act of 2022 implementation.
Supply Chain. 340B Issues. Outcomes based contracting/value-based arrangements. Genetically Targeted Therapies. PBM policy issues. H.R.5376 - Inflation Reduction Act of 2022 implementation. Most Favored Nation (MFN) policy.
Supply Chain. 340B Issues. Outcomes based contracting/value-based arrangements. Genetically Targeted Therapies. PBM policy issues. H.R.5376 - Inflation Reduction Act of 2022 implementation.
Center for Medicare and Medicaid Innovation (CMMI) policy issues. Drug Pricing. General Medicare and Medicaid Issues. Implementation of Inflation Reduction Act of 2022. H.R.1672 - Maintaining Investments in New Innovation Act. H.R.946 - ORPHAN Cures Act.
Drug pricing policy. Implementation of Inflation Reduction Act of 2022. S.864 - HELP Copays Act.
Drug pricing policy. Implementation of Inflation Reduction Act of 2022. S.864 - HELP Copays Act.
Drug pricing policy. Implementation of Inflation Reduction Act of 2022. S.864 - HELP Copays Act.
Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act
Client: GRAIL, INC. · Firm: TODD STRATEGY GROUP
Issues related to oncology and multi cancer early detection, including diagnostics and screening. H.R.2407 - Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act.
Labor, HHS and Education appropriations bill. H.R.3561 Monitored issues related to consumer directed health care and transparency. Issues related to surprise medical billing. Promoting Access to Treatments and Increasing Extremely Needed Transparency (PATIENT) Act of 2023. H.R. 4507 ACA Exchanges.
Appropriations. Monitored issues related to consumer directed health care and transparency. Issues related to surprise medical billing. Promoting Access to Treatments and Increasing Extremely Needed Transparency (PATIENT) Act of 2023. H.R.4507 - Transparency in Coverage Act of 2023.
Labor, HHS and Education appropriations bill. H.R.3561 Monitored issues related to consumer directed health care and transparency. Issues related to surprise medical billing. Promoting Access to Treatments and Increasing Extremely Needed Transparency (PATIENT) Act of 2023. H.R. 4507 ACA Exchanges.
Appropriations. Monitored issues related to consumer directed health care and transparency. Issues related to surprise medical billing. Promoting Access to Treatments and Increasing Extremely Needed Transparency (PATIENT) Act of 2023. H.R.4507 - Transparency in Coverage Act of 2023.
Consumer-directed health care and transparency. H.R.5378 - Lower Costs, More Transparency Act.
Consumer-directed health care and transparency. H.R.5378 - Lower Costs, More Transparency Act.
Medicare and Medicaid Issues. H.R.5547/S.476 - Maintaining Investments in New Innovation (MINI) Act. H.R.5539/S.3131 - ORPHAN Cures Act. Home infusion.
General issues related to rare disease and orphan drugs. Diagnostics for patients with rare disease. Multi-Cancer Early Detection. H.R.5547/S.476 - Maintaining Investments in New Innovation (MINI) Act. H.R.5539/S.3131 - ORPHAN Cures Act.
General issues related to rare disease and orphan drugs. Diagnostics for patients with rare disease. Multi-Cancer Early Detection. H.R.5547/S.476 - Maintaining Investments in New Innovation (MINI) Act. H.R.5539/S.3131 - ORPHAN Cures Act.
General issues related to rare disease and orphan drugs. Diagnostics for patients with rare disease. Multi-Cancer Early Detection. H.R.5547/S.476 - Maintaining Investments in New Innovation (MINI) Act. H.R.5539/S.3131 - ORPHAN Cures Act.
General issues related to rare disease and orphan drugs. Diagnostics for patients with rare disease. Multi-Cancer Early Detection. H.R.5547/S.476 - Maintaining Investments in New Innovation (MINI) Act. H.R.5539/S.3131 - ORPHAN Cures Act.
Medicare and Medicaid Issues H.R.5547/S.476 - Maintaining Investments in New Innovation (MINI) Act. H.R.5539/S.3131 - ORPHAN Cures Act. Home Infusion.
Medicare and Medicaid Issues H.R.5547/S.476 - Maintaining Investments in New Innovation (MINI) Act. H.R.5539/S.3131 - ORPHAN Cures Act. Home Infusion.
Medicare and Medicaid Issues H.R.5547/S.476 - Maintaining Investments in New Innovation (MINI) Act. H.R.5539/S.3131 - ORPHAN Cures Act. Home Infusion.
Maintaining Investments in New Innovation Act
Client: ALNYLAM PHARMACEUTICALS, INC. · Firm: TODD STRATEGY GROUP
Medicare and Medicaid Issues H.R.5547/S.476 - Maintaining Investments in New Innovation (MINI) Act. H.R.5539/S.3131 - ORPHAN Cures Act. Home Infusion.
Maintaining Investments in New Innovation Act
Client: ALNYLAM PHARMACEUTICALS, INC. · Firm: TODD STRATEGY GROUP
Medicare and Medicaid Issues. H.R.5547/S.476 - Maintaining Investments in New Innovation (MINI) Act. H.R.5539/S.3131 - ORPHAN Cures Act. Home infusion.
Maintaining Investments in New Innovation Act
Client: ALEXION PHARMACEUTICALS, INC. · Firm: TODD STRATEGY GROUP
General issues related to rare disease and orphan drugs. Diagnostics for patients with rare disease. Multi-Cancer Early Detection. H.R.5547/S.476 - Maintaining Investments in New Innovation (MINI) Act. H.R.5539/S.3131 - ORPHAN Cures Act.
Maintaining Investments in New Innovation Act
Client: ALEXION PHARMACEUTICALS, INC. · Firm: TODD STRATEGY GROUP
General issues related to rare disease and orphan drugs. Diagnostics for patients with rare disease. Multi-Cancer Early Detection. H.R.5547/S.476 - Maintaining Investments in New Innovation (MINI) Act. H.R.5539/S.3131 - ORPHAN Cures Act.
Maintaining Investments in New Innovation Act
Client: ALNYLAM PHARMACEUTICALS, INC. · Firm: TODD STRATEGY GROUP
Medicare and Medicaid Issues H.R.5547/S.476 - Maintaining Investments in New Innovation (MINI) Act. H.R.5539/S.3131 - ORPHAN Cures Act. Home Infusion.
Maintaining Investments in New Innovation Act
Client: ALNYLAM PHARMACEUTICALS, INC. · Firm: TODD STRATEGY GROUP
Medicare and Medicaid Issues H.R.5547/S.476 - Maintaining Investments in New Innovation (MINI) Act. H.R.5539/S.3131 - ORPHAN Cures Act. Home Infusion.
Maintaining Investments in New Innovation Act
Client: ALEXION PHARMACEUTICALS, INC. · Firm: TODD STRATEGY GROUP
General issues related to rare disease and orphan drugs. Diagnostics for patients with rare disease. Multi-Cancer Early Detection. H.R.5547/S.476 - Maintaining Investments in New Innovation (MINI) Act. H.R.5539/S.3131 - ORPHAN Cures Act.
Maintaining Investments in New Innovation Act
Client: ALEXION PHARMACEUTICALS, INC. · Firm: TODD STRATEGY GROUP
General issues related to rare disease and orphan drugs. Diagnostics for patients with rare disease. Multi-Cancer Early Detection. H.R.5547/S.476 - Maintaining Investments in New Innovation (MINI) Act. H.R.5539/S.3131 - ORPHAN Cures Act.
Advancing Menopause Care and Mid-Life Women’s Health Act
Client: ASTELLAS PHARMA US, INC. · Firm: TODD STRATEGY GROUP
Value of Prescription Drugs, Drug pricing, Biopharmaceutical Innovation and Patient Policy Issues. PSA Screening for HIM Act; H.R. 8223/S. 4246 Advancing Menopause and Mid-Life Womens Health Act. Pharmacy Benefit Manager reform. Issues related to March-In.
Advancing Menopause Care and Mid-Life Women’s Health Act
Client: ASTELLAS PHARMA US, INC. · Firm: TODD STRATEGY GROUP
Value of Prescription Drugs, Drug pricing, Biopharmaceutical Innovation and Patient Policy Issues. PSA Screening for HIM Act; H.R. 8223/S. 4246 Advancing Menopause and Mid-Life Womens Health Act. Pharmacy Benefit Manager reform. Issues related to March-In.
Advancing Menopause Care and Mid-Life Women’s Health Act
Client: ASTELLAS PHARMA US, INC. · Firm: TODD STRATEGY GROUP
Value of Prescription Drugs. Drug pricing. Biopharmaceutical Innovation and Patient Policy Issues. PSA Screening for HIM Act. H.R.8223/S.4246 - Advancing Menopause Care and Mid-Life Womens Health Act. Pharmacy Benefit Manager reform. Issues related to March-In
Drug Pricing. H.R. 830 HELP Copays Act.
Drug Pricing. H.R. 830 HELP Copays Act.
340B. Home Infusion for Part B Products. H.R.830 - HELP Copays Act.
Pharmacy Benefit Managers. Tort litigation reform. Health Care Supply Chain. S.1375/H.R.830 - HELP Copays Act.
Pharmacy Benefit Managers. 340B. Tort Litigation reform. Health care supply chain. S.1375/HR 830 - HELP Copays Act. Inflation Reduction Act Implementation.
340B Program. Home Infusion for Part B Products. H.R.830 - HELP Copays Act. Medicare Reimbursement for New Technologies.
Drug Pricing. H.R. 830 HELP Copays Act.
340B. Home Infusion for Part B Products. H.R.830 - HELP Copays Act.
Medicare Reimbursement for New Technologies. 340B. Home Infusion for Part B Products. H.R.830 - HELP Copays Act.
Pharmacy Benefit Managers. 340B. Tort Litigation reform. Health care supply chain. S.1375/HR 830 - HELP Copays Act. Inflation Reduction Act Implementation.
Pharmacy Benefit Managers. 340B. Tort litigation reform. Health Care Supply Chain. S.1375/H.R.830 - HELP Copays Act.
340B. Home Infusion for Part B Products. H.R.830 - HELP Copays Act.
Drug Pricing. H.R. 830 HELP Copays Act.
Drug Pricing. H.R. 830 HELP Copays Act.
Pharmacy Benefit Managers. 340B. Tort Litigation reform. Health care supply chain. S.1375/HR 830 - HELP Copays Act. Inflation Reduction Act Implementation.
Pharmacy Benefit Managers. 340B. Tort litigation reform. Health Care Supply Chain. S.1375/H.R.830 - HELP Copays Act.
Pharmacy Benefit Managers. 340B. Tort Litigation reform. Health care supply chain. S.1375/HR 830 - HELP Copays Act. Inflation Reduction Act Implementation.
Pharmacy Benefit Managers. 340B. Tort Litigation reform. Health care supply chain. S.1375/HR 830 - HELP Copays Act. Inflation Reduction Act Implementation.
Pharmacy Benefit Managers. Tort litigation reform. Health Care Supply Chain. S.1375/H.R.830 - HELP Copays Act.
Pharmacy Benefit Managers. 340B. Tort Litigation reform. Health care supply chain. S.1375/HR 830 - HELP Copays Act. Inflation Reduction Act Implementation.
Patent Issues. Support for PREVAIL Act (S.2220). Support for Patent Eligibility Restoration Act (PERA) (S. 2140).
Patent Issues. Support for PREVAIL Act (S.2220). Support for Patent Eligibility Restoration Act (PERA) (S. 2140).
Patent Issues. Support for PREVAIL Act (S.2220). Support for Patent Eligibility Restoration Act (PERA) (S. 2140).
Patent Issues. Support for PREVAIL Act (S.2220). Support for Patent Eligibility Restoration Act (PERA) (S. 2140).
Patent Issues. Support for PREVAIL Act (S.2220). Support for Patent Eligibility Restoration Act (PERA) (S. 2140).
Patent Issues. Support for PREVAIL Act (S.2220). Support for Patent Eligibility Restoration Act (PERA) (S. 2140).
General issues related to rare disease and orphan drugs. Diagnostics for patients with rare disease. Multi-Cancer Early Detection. H.R.5547/S.476 - Maintaining Investments in New Innovation (MINI) Act. H.R.5539/S.3131 - ORPHAN Cures Act.
Medicare and Medicaid Issues H.R.5547/S.476 - Maintaining Investments in New Innovation (MINI) Act. H.R.5539/S.3131 - ORPHAN Cures Act. Home Infusion.
General issues related to rare disease and orphan drugs. Diagnostics for patients with rare disease. Multi-Cancer Early Detection. H.R.5547/S.476 - Maintaining Investments in New Innovation (MINI) Act. H.R.5539/S.3131 - ORPHAN Cures Act.
Medicare and Medicaid Issues. H.R.5547/S.476 - Maintaining Investments in New Innovation (MINI) Act. H.R.5539/S.3131 - ORPHAN Cures Act. Home infusion.
General issues related to rare disease and orphan drugs. Diagnostics for patients with rare disease. Multi-Cancer Early Detection. H.R.5547/S.476 - Maintaining Investments in New Innovation (MINI) Act. H.R.5539/S.3131 - ORPHAN Cures Act.
2025 · third_quarter · Q3
Organ procurement regulations. Increasing access to organ transplant.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
PMI US CORPORATE SERVICES INC. via TODD STRATEGY GROUP
2025 · third_quarter · Q3
Discussions related to implementation of P.L. 111-31 Family Smoking Prevention and Tobacco Control Act. Discussions related to tobacco harm reduction. Discussions related to enforcement of illicit tobacco products, including importation of counterfeit products. Discussions related to user fees for tobacco and electronic nicotine delivery system products. Discussions related to efforts to prevent youth access to tobacco products.
Discussions concerning the FY 2024 appropriations bills; provisions related to FDA regulation of tobacco.
Discussions concerning federal funding related to the Centers for Disease Control and Prevention.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
OTSUKA AMERICA PHARMACEUTICAL, INC. via TODD STRATEGY GROUP
2025 · third_quarter · Q3
Drug Pricing Policy. Issues relating to mental health as a chronic condition. Agitation in Alzheimer's.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
NOVARTIS, INC. via TODD STRATEGY GROUP
2025 · third_quarter · Q3
Supply Chain. 340B Issues. Outcomes based contracting/value-based arrangements. Genetically Targeted Therapies. PBM policy issues. H.R.5376 - Inflation Reduction Act of 2022 implementation. Most Favored Nation (MFN) policy.
Center for Medicare and Medicaid Innovation (CMMI) policy issues. Drug Pricing. General Medicare and Medicaid Issues. Implementation of Inflation Reduction Act of 2022. H.R.1672 - Maintaining Investments in New Innovation Act. S.3131 / H.R.5539 - ORPHAN Cures Act. S.832/H.R.1492: Ensuring Pathways to Innovative Cures Act of 2025 or the EPIC Act of 2025.
Tariffs.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
MERCK & CO., INC. via TODD STRATEGY GROUP
2025 · third_quarter · Q3
340B issues. Antimicrobial resistance. Supply Chain. Vaccine issues. Food and Drug Administration issues.
Drug Pricing. S.864 - HELP Copays Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
MCKESSON CORPORATION via TODD STRATEGY GROUP
2025 · third_quarter · Q3
General Medicare/Medicaid Issues. Transparency Requirements. Emergency Preparedness.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
ILLUMINA, INC. via TODD STRATEGY GROUP
2025 · third_quarter · Q3
General discussions related to the Food and Drug Administration's regulation of diagnostics. General health care procurement policy issues.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
EMD SERONO INC. via TODD STRATEGY GROUP
2025 · third_quarter · Q3
Drug pricing policy. Implementation of Inflation Reduction Act of 2022. S.864 - HELP Copays Act.
PBM Reform. 340B Program. Supply chain. Issues pertaining to reproductive health and access and coverage of infertility treatments and care.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
DH DIAGNOSTICS LLC via TODD STRATEGY GROUP
2025 · third_quarter · Q3
Issues related to diagnostic testing, antimicrobial resistance, Alzheimers. Oncology/Artificial Intelligence. HCV Testing.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
THE COALITION FOR 21ST CENTURY MEDICINE via TODD STRATEGY GROUP
2025 · third_quarter · Q3
Medicare coverage and reimbursement for diagnostics. FDA LDT Regulation. Prior Authorization for Medicare Advantage. Medicare contractor reform.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
BRISTOL-MYERS SQUIBB COMPANY via TODD STRATEGY GROUP
2025 · third_quarter · Q3
Biosimilars reimbursement issues. Supply Chain Issues. Pharmacy Benefit Manager Reform.
Medicare/Medicaid payment reform. Implementation of Inflation Reduction Act of 2022. 340B Program.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
BIOGEN, INC. via TODD STRATEGY GROUP
2025 · third_quarter · Q3
Alzheimer's Disease. Medicare Reimbursement for Prescription Drugs. Screening and Diagnosis, PET scan coverage and reimbursement and dementia care.
Drug pricing and supply chain issues, rare diseases, gene therapy and value based arrangements. Implementation of Inflation Reduction Act of 2022. Issues related to maternal health.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BAYER CORPORATION via TODD STRATEGY GROUP
2025 · third_quarter · Q3
Drug pricing. Implementation of Inflation Reduction Act of 2022.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ALNYLAM PHARMACEUTICALS, INC. via TODD STRATEGY GROUP
2025 · third_quarter · Q3
Medicare and Medicaid Issues H.R.1672 - Maintaining Investments in New Innovation Act. H.R.946 - ORPHAN Cures Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ALEXION PHARMACEUTICALS, INC. via TODD STRATEGY GROUP
2025 · second_quarter · 2T
340B Program. Home Infusion for Part B Products. S.864 - HELP Copays Act. Medicare Reimbursement for New Technologies.
General issues related to rare disease and orphan drugs. Diagnostics for patients with rare disease. Multi-Cancer Early Detection. H.R.1672 - Maintaining Investments in New Innovation Act. H.R.946 - ORPHAN Cures Act.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
VANTIVE US HEALTHCARE LLC via TODD STRATEGY GROUP
2025 · third_quarter · Q3
Kidney and dialysis care.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
U.S. CHAMBER OF COMMERCE GLOBAL INNOVATION POLICY CENTER via TODD STRATEGY GROUP
2025 · third_quarter · Q3
Copyright issues. Intellectual property protection.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
TRUIST FINANCIAL CORPORATION via TODD STRATEGY GROUP
2025 · third_quarter · Q3
Banking Regulatory Reform Issues.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SIEMENS HEALTHINEERS via TODD STRATEGY GROUP
2025 · third_quarter · Q3
General Medicare / Medicaid Issues. Medicare Rulemaking. Medicare reimbursement for radiation oncology. Telehealth.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
SIDECAR HEALTH via TODD STRATEGY GROUP
2025 · third_quarter · Q3
Consumer-directed health care and transparency.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA via TODD STRATEGY GROUP
2025 · third_quarter · Q3
Part D changes. Prescription drug payment reform. 340B issues. Onshoring. S.864 - HELP Copays Act. General Medicare and Medicaid Issues.
Drug Pricing and Access. Pharmaceutical Supply Chain. Pharmacy Benefit Managers.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
THE ORTHOFORUM via TODD STRATEGY GROUP
2025 · third_quarter · Q3
Physician Reimbursement. Physician-owned hospitals. Medicare and Medicaid Issues. Payment Reform. Price transparency.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
OSRX PHARMACEUTICALS via TODD STRATEGY GROUP
2025 · second_quarter · 2T
FDA Regulations.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
NOVO NORDISK INC. via TODD STRATEGY GROUP
2025 · third_quarter · Q3
Implementation of Inflation Reduction Act. Pharmacy Benefit Manager Reform, Health care supply chain. 340B. Treat and Reduce Obesity Act.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
AMERICAN POLICY VENTURES ACTION via TODD STRATEGY GROUP
2025 · third_quarter · 3A
General education around APVA and its mission to promote American competitiveness, including issues related to tax policy and economic opportunity and growth.
General education around APVA and its mission to promote American competitiveness, including issues related to tax policy and economic opportunity and growth.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
MYRIAD GENETICS, INC. via TODD STRATEGY GROUP
2025 · third_quarter · Q3
Prior Authorization for Medicare Advantage.
Filing targets: HOUSE OF REPRESENTATIVES
MEDICAL COUNTERMEASURES COALITION via TODD STRATEGY GROUP
2025 · third_quarter · Q3
Sustainability of the public health emergency medical countermeasure enterprise.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
KALDEROS, INC. via TODD STRATEGY GROUP
2025 · third_quarter · Q3
Government pricing discounts. Claims adjudication.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
JOHNSON & JOHNSON SERVICES, INC. via TODD STRATEGY GROUP
2025 · third_quarter · Q3
Pharmacy Benefit Managers. 340B. Tort Litigation reform. Health care supply chain. S.864 - HELP Copays Act. Inflation Reduction Act Implementation.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
HOSPICE COMPASSUS via TODD STRATEGY GROUP
2025 · second_quarter · 2T
Preserving Access to Home Health Act. Quality, payment and regulatory compliance requirements for hospice, home health, home infusion, advanced illness and palliative care.
Palliative, home health, home infusion and Medicare Advantage. Medicare/Hospice issues.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
GLAXOSMITHKLINE LLC via TODD STRATEGY GROUP
2025 · third_quarter · Q3
Medicare and Medicaid issues. 340B Issues.
Drug pricing. Implementation of IRA. Supply chain issues.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
GILEAD SCIENCES, INC. via TODD STRATEGY GROUP
2025 · third_quarter · Q3
Prescription drug payment reform. Supply Chain. 340B.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
GENMAB via TODD STRATEGY GROUP
2025 · third_quarter · Q3
Prescription Drug Pricing. Implementation of Inflation Reduction Act of 2022.
General Medicare/Medicaid Issues. 340B Issues.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
GENENTECH, INC. via TODD STRATEGY GROUP
2025 · third_quarter · Q3
Medicare and Medicaid payment issues. 340B. Implementation of Inflation Reduction Act of 2022.
Prescription drug payment reform. Supply chain. Strategic National Stockpile.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
FERRING PHARMACEUTICALS INC. via TODD STRATEGY GROUP
2025 · third_quarter · Q3
Issues pertaining to reproductive health and access and coverage of infertility treatments and care. Issues related to infectious disease and hospital acquired infections.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
EXELIXIS, INC. via TODD STRATEGY GROUP
2025 · third_quarter · Q3
Policy to advance pharmaceutical research and development. 340B.
Implementation of Inflation Reduction Act of 2022.
Intellectual property.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
ELI LILLY AND COMPANY via TODD STRATEGY GROUP
2025 · third_quarter · Q3
Alzheimer's Disease. Anti Obesity Medication.
Medicare/Medicaid Coverage and Reimbursement. PDUFA. 340B Program.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BIODESIX, INC. via TODD STRATEGY GROUP
2025 · third_quarter · Q3
Medicare reimbursement for diagnostics. Medicare Contractor Reform.
Lab test regulatory and reimbursement reform.
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
ASTELLAS PHARMA US, INC. via TODD STRATEGY GROUP
2025 · third_quarter · Q3
Prescription drug pricing.
Prostate cancer screening. Women's health.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AMGEN INC. via TODD STRATEGY GROUP
2025 · third_quarter · Q3
Medicare/Medicaid payment reform. Implementation of Inflation Reduction Act of 2022.
Prescription Drug Pricing Policy. Supply Chain Issues.
Prescription drug pricing policy.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
AMERICAN POLICY VENTURES ACTION via TODD STRATEGY GROUP
2025 · third_quarter · Q3
General education around APVA and its mission to promote American competitiveness, including issues related to tax policy and economic opportunity and growth.
General education around APVA and its mission to promote American competitiveness, including issues related to tax policy and economic opportunity and growth.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AMERICAN MEDICAL ASSOCIATION via TODD STRATEGY GROUP
2025 · third_quarter · Q3
Physician Payment Reform.
Medicare and Medicaid Issues.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AMERICAN COLLEGE OF RADIOLOGY via TODD STRATEGY GROUP
2025 · third_quarter · Q3
Medicare Physician Fee Schedule Provider Reimbursement. PAMA AUC. Medicare and Medicaid Issues. Value of imaging.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
ALKERMES, INC. via TODD STRATEGY GROUP
2025 · third_quarter · Q3
Prescription drug pricing, including MDRP Substance Use Disorder Policy. Implementation of Inflation Reduction Act of 2022. Medicaid drug rebate program.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
PMI US CORPORATE SERVICES INC. via TODD STRATEGY GROUP
2025 · first_quarter · RA
Tobacco harm reduction. Enforcement of illicit tobacco products, including importation of counterfeit products. User fees for tobacco and electronic nicotine delivery system products. Efforts to prevent youth access to tobacco products. Appropriations.
Tobacco harm reduction. Enforcement of illicit tobacco products, including importation of counterfeit products. User fees for tobacco and electronic nicotine delivery system products. Efforts to prevent youth access to tobacco products. Appropriations.
Tobacco harm reduction. Enforcement of illicit tobacco products, including importation of counterfeit products. User fees for tobacco and electronic nicotine delivery system products. Efforts to prevent youth access to tobacco products. Appropriations.
VANTIVE US HEALTHCARE LLC via TODD STRATEGY GROUP
2025 · second_quarter · Q2
Kidney and dialysis care.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
U.S. CHAMBER OF COMMERCE GLOBAL INNOVATION POLICY CENTER via TODD STRATEGY GROUP
2025 · second_quarter · Q2
Copyright issues. Intellectual property protection.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
TRUIST FINANCIAL CORPORATION via TODD STRATEGY GROUP
2025 · second_quarter · Q2
Banking Regulatory Reform Issues.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
TAKEDA PHARMACEUTICALS AMERICA, INC. via TODD STRATEGY GROUP
2025 · second_quarter · Q2
Rare Disease Issues.
General Medicare/Medicaid Issues. Implementation of Inflation Reduction Act of 2022.
Filing targets: HOUSE OF REPRESENTATIVES
SOUTHWEST TRANSPLANT ALLIANCE via TODD STRATEGY GROUP
2025 · second_quarter · Q2
Organ procurement regulations. Increasing access to organ transplant.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
SIEMENS HEALTHINEERS via TODD STRATEGY GROUP
2025 · second_quarter · Q2
General Medicare / Medicaid Issues. Medicare Rulemaking. Medicare reimbursement for radiation oncology. Telehealth.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
SIDECAR HEALTH via TODD STRATEGY GROUP
2025 · second_quarter · Q2
Consumer-directed health care and transparency.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PMI US CORPORATE SERVICES INC. via TODD STRATEGY GROUP
2025 · second_quarter · Q2
Discussions concerning the FY 2024 appropriations bills; provisions related to FDA regulation of tobacco.
Discussions concerning federal funding related to the Centers for Disease Control and Prevention.
Discussions related to implementation of P.L. 111-31 Family Smoking Prevention and Tobacco Control Act. Discussions related to tobacco harm reduction. Discussions related to enforcement of illicit tobacco products, including importation of counterfeit products. Discussions related to user fees for tobacco and electronic nicotine delivery system products. Discussions related to efforts to prevent youth access to tobacco products.
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA via TODD STRATEGY GROUP
2025 · second_quarter · Q2
Drug Pricing and Access. Pharmaceutical Supply Chain. Pharmacy Benefit Managers.
Part D changes. Prescription drug payment reform. 340B issues. Onshoring. S.864 - HELP Copays Act. General Medicare and Medicaid Issues.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
OTSUKA AMERICA PHARMACEUTICAL, INC. via TODD STRATEGY GROUP
2025 · second_quarter · Q2
Drug Pricing Policy. Issues relating to mental health as a chronic condition. Agitation in Alzheimer's.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
OSRX PHARMACEUTICALS via TODD STRATEGY GROUP
2025 · second_quarter · Q2
FDA Regulations.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
THE ORTHOFORUM via TODD STRATEGY GROUP
2025 · second_quarter · Q2
Physician Reimbursement. Physician-owned hospitals. Medicare and Medicaid Issues. Payment Reform. Price transparency.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
NOVO NORDISK INC. via TODD STRATEGY GROUP
2025 · second_quarter · Q2
Implementation of Inflation Reduction Act. Pharmacy Benefit Manager Reform, Health care supply chain. 340B. Treat and Reduce Obesity Act.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
NOVARTIS, INC. via TODD STRATEGY GROUP
2025 · second_quarter · Q2
Center for Medicare and Medicaid Innovation (CMMI) policy issues. Drug Pricing. General Medicare and Medicaid Issues. Implementation of Inflation Reduction Act of 2022. H.R.1672 - Maintaining Investments in New Innovation Act. S.3131 / H.R.5539 - ORPHAN Cures Act. S.832 - EPIC Act of 2025.
Traffic policies.
Supply Chain. 340B Issues. Outcomes based contracting/value-based arrangements. Genetically Targeted Therapies. PBM policy issues. H.R.5376 - Inflation Reduction Act of 2022 implementation.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
NOMI HEALTH, INC. via TODD STRATEGY GROUP
2025 · second_quarter · Q2
General education on Nomi Health. Prior authorization. Issues related to healthcare cost transparency.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
MYRIAD GENETICS, INC. via TODD STRATEGY GROUP
2025 · second_quarter · Q2
Prior Authorization for Medicare Advantage.
Filing targets: HOUSE OF REPRESENTATIVES
MERCK & CO., INC. via TODD STRATEGY GROUP
2025 · second_quarter · Q2
340B issues. Antimicrobial resistance. Supply Chain. Vaccine issues. Food and Drug Administration issues.
Drug Pricing. S.864 - HELP Copays Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
MEDICAL COUNTERMEASURES COALITION via TODD STRATEGY GROUP
2025 · second_quarter · Q2
Sustainability of the public health emergency medical countermeasure enterprise.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
MCKESSON CORPORATION via TODD STRATEGY GROUP
2025 · second_quarter · Q2
General Medicare/Medicaid Issues. Transparency Requirements. Emergency Preparedness.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
KALDEROS, INC. via TODD STRATEGY GROUP
2025 · second_quarter · Q2
Government pricing discounts. Claims adjudication.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
JOHNSON & JOHNSON SERVICES, INC. via TODD STRATEGY GROUP
2025 · second_quarter · Q2
Pharmacy Benefit Managers. 340B. Tort Litigation reform. Health care supply chain. S.864 - HELP Copays Act. Inflation Reduction Act Implementation.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
ILLUMINA, INC. via TODD STRATEGY GROUP
2025 · second_quarter · Q2
General discussions related to the Food and Drug Administration's regulation of diagnostics. General health care procurement policy issues.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
HOSPICE COMPASSUS via TODD STRATEGY GROUP
2025 · second_quarter · Q2
Preserving Access to Home Health Act. Quality, payment and regulatory compliance requirements for hospice, home health, home infusion, advanced illness and palliative care.
Palliative, home health, home infusion and Medicare Advantage. Medicare/Hospice issues.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
GLAXOSMITHKLINE LLC via TODD STRATEGY GROUP
2025 · second_quarter · Q2
Medicare and Medicaid issues. 340B Issues.
Drug pricing. Implementation of IRA. Supply chain issues.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
GILEAD SCIENCES, INC. via TODD STRATEGY GROUP
2025 · second_quarter · Q2
Prescription drug payment reform. Supply Chain. 340B.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
GENMAB via TODD STRATEGY GROUP
2025 · second_quarter · Q2
Prescription Drug Pricing. Implementation of Inflation Reduction Act of 2022.
General Medicare/Medicaid Issues. 340B Issues.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
GENENTECH, INC. via TODD STRATEGY GROUP
2025 · second_quarter · Q2
Medicare and Medicaid payment issues. 340B. Implementation of Inflation Reduction Act of 2022.
Prescription drug payment reform. Supply chain. Strategic National Stockpile.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
FLEXCARE via TODD STRATEGY GROUP
2025 · first_quarter · 1T
Healthcare Policy Regarding Hospital Workforce.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
FERRING PHARMACEUTICALS INC. via TODD STRATEGY GROUP
2025 · second_quarter · Q2
Issues pertaining to reproductive health and access and coverage of infertility treatments and care. Issues related to infectious disease and hospital acquired infections.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
EXELIXIS, INC. via TODD STRATEGY GROUP
2025 · second_quarter · Q2
Policy to advance pharmaceutical research and development. 340B.
Implementation of Inflation Reduction Act of 2022.
Intellectual property.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
EMD SERONO INC. via TODD STRATEGY GROUP
2025 · second_quarter · Q2
Drug pricing policy. Implementation of Inflation Reduction Act of 2022. S.864 - HELP Copays Act.
PBM Reform. 340B Program. Supply chain. Issues pertaining to reproductive health and access and coverage of infertility treatments and care.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ELI LILLY AND COMPANY via TODD STRATEGY GROUP
2025 · second_quarter · Q2
Alzheimer's Disease. Anti Obesity Medication.
Medicare/Medicaid Coverage and Reimbursement. PDUFA. 340B Program.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
DH DIAGNOSTICS LLC via TODD STRATEGY GROUP
2025 · second_quarter · Q2
Issues related to diagnostic testing, antimicrobial resistance, Alzheimers. Oncology/Artificial Intelligence. HCV Testing.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
THE COALITION FOR 21ST CENTURY MEDICINE via TODD STRATEGY GROUP
2025 · second_quarter · Q2
Medicare coverage and reimbursement for diagnostics. FDA LDT Regulation. Prior Authorization for Medicare Advantage. Medicare contractor reform.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
BRISTOL-MYERS SQUIBB COMPANY via TODD STRATEGY GROUP
2025 · second_quarter · Q2
Medicare/Medicaid payment reform. Implementation of Inflation Reduction Act of 2022. 340B Program.
Biosimilars reimbursement issues. Supply Chain Issues. Pharmacy Benefit Manager Reform.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
BIOGEN, INC. via TODD STRATEGY GROUP
2025 · second_quarter · Q2
Alzheimer's Disease. Medicare Reimbursement for Prescription Drugs. Screening and Diagnosis, PET scan coverage and reimbursement and dementia care.
Drug pricing and supply chain issues, rare diseases, gene therapy and value based arrangements. Implementation of Inflation Reduction Act of 2022. Issues related to maternal health.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BIODESIX, INC. via TODD STRATEGY GROUP
2025 · second_quarter · Q2
Medicare reimbursement for diagnostics. Medicare Contractor Reform.
Lab test regulatory and reimbursement reform.
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
BAYER CORPORATION via TODD STRATEGY GROUP
2025 · second_quarter · Q2
Drug pricing. Implementation of Inflation Reduction Act of 2022.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ASTELLAS PHARMA US, INC. via TODD STRATEGY GROUP
2025 · second_quarter · Q2
Prescription drug pricing. Prostate cancer screening. Women's health.
Prescription drug pricing. Prostate cancer screening. Women's health.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AMGEN INC. via TODD STRATEGY GROUP
2025 · second_quarter · Q2
Medicare/Medicaid payment reform. Implementation of Inflation Reduction Act of 2022.
Prescription Drug Pricing Policy. Supply Chain Issues.
Prescription drug pricing policy.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
AMERICAN POLICY VENTURES ACTION via TODD STRATEGY GROUP
2025 · second_quarter · Q2
General education around APVA and its mission to promote American competitiveness, including issues related to tax policy and economic opportunity and growth.
General education around APVA and its mission to promote American competitiveness, including issues related to tax policy and economic opportunity and growth.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AMERICAN MEDICAL ASSOCIATION via TODD STRATEGY GROUP
2025 · second_quarter · Q2
Physician Payment Reform.
Medicare and Medicaid Issues.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AMERICAN COLLEGE OF RADIOLOGY via TODD STRATEGY GROUP
2025 · second_quarter · Q2
Medicare Physician Fee Schedule Provider Reimbursement. PAMA AUC. Medicare and Medicaid Issues. Value of imaging.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
ALNYLAM PHARMACEUTICALS, INC. via TODD STRATEGY GROUP
2025 · second_quarter · Q2
Medicare and Medicaid Issues H.R.1672 - Maintaining Investments in New Innovation Act. H.R.946 - ORPHAN Cures Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ALKERMES, INC. via TODD STRATEGY GROUP
2025 · second_quarter · Q2
Prescription drug pricing, including MDRP Substance Use Disorder Policy. Implementation of Inflation Reduction Act of 2022. Medicaid drug rebate program.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
ALEXION PHARMACEUTICALS, INC. via TODD STRATEGY GROUP
2025 · second_quarter · Q2
340B Program. Home Infusion for Part B Products. S.864 - HELP Copays Act. Medicare Reimbursement for New Technologies.
General issues related to rare disease and orphan drugs. Diagnostics for patients with rare disease. Multi-Cancer Early Detection. H.R.1672 - Maintaining Investments in New Innovation Act. H.R.946 - ORPHAN Cures Act.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
GLAXOSMITHKLINE LLC via TODD STRATEGY GROUP
2025 · first_quarter · Q1
Medicare and Medicaid issues. 340B Issues.
Drug pricing. Implementation of IRA. Supply chain issues.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
GLAXOSMITHKLINE LLC via TODD STRATEGY GROUP
2025 · first_quarter · RR
Medicare and Medicaid issues. 340B Issues. Drug pricing. Implementation of IRA. Supply chain issues.
Medicare and Medicaid issues. 340B Issues. Drug pricing. Implementation of IRA. Supply chain issues.
THE COALITION FOR 21ST CENTURY MEDICINE via TODD STRATEGY GROUP
2025 · first_quarter · Q1
Medicare coverage and reimbursement for diagnostics. FDA LDT Regulation. Prior Authorization for Medicare Advantage. Medicare contractor reform.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
NOMI HEALTH, INC. via TODD STRATEGY GROUP
2025 · first_quarter · Q1
General education on Nomi Health. Prior authorization. Healthcare cost transparency
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
NOMI HEALTH, INC. via TODD STRATEGY GROUP
2025 · first_quarter · RA
General education on Nomi Health. Prior authorization. Healthcare cost transparency.
VANTIVE US HEALTHCARE LLC via TODD STRATEGY GROUP
2025 · first_quarter · Q1
Kidney and dialysis care.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS)
VANTIVE US HEALTHCARE LLC via TODD STRATEGY GROUP
2025 · first_quarter · RR
Kidney and dialysis care.
U.S. CHAMBER OF COMMERCE GLOBAL INNOVATION POLICY CENTER via TODD STRATEGY GROUP
2025 · first_quarter · Q1
Copyright issues Intellectual property protection. March-in rights.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Filing targets: HOUSE OF REPRESENTATIVES, SENATE